DCOY — Decoy Therapeutics Inc.

Salarius Pharmaceuticals Q2 2022 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $4.7 million ($0.09 per share) for Q2 2022, compared to a net loss of $3.1 million ($0.07 per share) in Q2 2021. The increase was attributed to higher operating expenses and the absence of grant revenue.
• Research and Development Expenses: $2.9 million in Q2 2022, up from $2.1 million in Q2 2021, primarily due to spending on the targeted protein degradation technology.
• General and Administrative Expenses: Increased to $1.8 million from $1.6 million year-over-year due to higher personnel costs.
• Year-to-Date Net Loss: $10.8 million ($0.22 per share) for the first half of 2022, compared to $4.9 million ($0.13 per share) in the same period of 2021.
• Cash Position: As of June 30, 2022, cash and cash equivalents totaled $22.6 million, down from $29.2 million at the end of 2021, expected to fund operations into 2023.

2. Strategic Updates and Business Highlights

• Seclidemstat Program: Enrollment in the Phase 1/2 study for Ewing’s and FET-rearranged sarcomas is progressing well, with 15 clinical sites and plans for more. Interim data is expected later this year.
• Collaboration with Volition Rx: A partnership to utilize rapid epigenetic profiling to study biomarkers for seclidemstat, aiming for non-invasive patient monitoring.
• SP-3164 Development: Progressing towards an IND submission in the first half of 2023. The company has completed pre-IND meetings with the FDA and is conducting IND enabling studies.

3. Forward Guidance and Outlook

• Salarius anticipates a busy second half of 2022 with multiple data updates from both seclidemstat and SP-3164 programs. Interim clinical data from seclidemstat is expected by year-end, and preclinical data for SP-3164 will be shared later this year.
• Management expressed confidence in the potential of both drug candidates to address significant unmet medical needs in cancer treatment.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The company reported a significant increase in net losses year-over-year, raising concerns about financial sustainability without additional revenue sources.
• Absence of Grant Revenue: The lack of grant revenue in 2022, compared to $1.8 million in the first half of 2021, poses a challenge for funding operations.
• Market Competition: The competitive landscape for cancer therapies, particularly in the protein degradation space, could impact Salarius's ability to secure partnerships or market share.

5. Notable Q&A Insights

• Enrollment Status: Management confirmed that enrollment for the seclidemstat trial is progressing well, with several prestigious sites added.
• Data Dissemination Plans: There is flexibility in how interim data will be released, with options for press releases or conference presentations, depending on the data's readiness and ethical considerations.
• IND Enabling Studies for SP-3164: The company is on track with IND enabling studies, aiming for submission in the first half of 2023, with updates on mechanism of action expected at upcoming conferences.

Overall, Salarius Pharmaceuticals is focused on advancing its clinical programs while managing financial challenges and preparing for a potentially impactful second half of 2022.